The changing landscape of hepatocellular carcinoma: Etiology, genetics, and therapy

Erik S. Knudsen, Purva Gopal, Amit G. Singal

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer death and has proved to be highly refractory to treatment. Extensive analysis of the disease has demonstrated that it arises predominantly in response to high-risk etiological challenges, most notably hepatitis virus. However, with evolving vaccination and the obesity epidemic, progressively more cases are associated with underlying metabolic dysfunction. Pathologically diverse forms of HCC are observed, and recent sequencing analysis has defined common events that target well-known cancer pathways including β-catenin/Axin, TP53, and RB/CDKN2A, as well as frequent aberrations in chromatin remodeling factors. However, there are a myriad of low frequency genetic events that make each HCC case unique. Gene expression profiling approaches have successfully been deployed for prognostic assessment of hepatocellular carcinoma and to detect the earliest stages of disease. Despite more extensive research, systemic treatment for HCC is exceedingly limited, with only a handful of drugs providing benefit. Ongoing clinical trials are attempting to exploit specific biological dependencies of HCC to improve the dismal prognosis. Overall, the future of HCC treatment will rely on an understanding of the interplay between etiological factors, molecular features of disease, and rational therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)574-583
Number of pages10
JournalAmerican Journal of Pathology
Volume184
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Genetic Therapy
Hepatocellular Carcinoma
Catenins
Hepatitis Viruses
Chromatin Assembly and Disassembly
Gene Expression Profiling
Therapeutics
Cause of Death
Neoplasms
Vaccination
Obesity
Clinical Trials
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The changing landscape of hepatocellular carcinoma : Etiology, genetics, and therapy. / Knudsen, Erik S.; Gopal, Purva; Singal, Amit G.

In: American Journal of Pathology, Vol. 184, No. 3, 03.2014, p. 574-583.

Research output: Contribution to journalArticle

@article{31a2e88174514d6d902cb3ac9e6c640d,
title = "The changing landscape of hepatocellular carcinoma: Etiology, genetics, and therapy",
abstract = "Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer death and has proved to be highly refractory to treatment. Extensive analysis of the disease has demonstrated that it arises predominantly in response to high-risk etiological challenges, most notably hepatitis virus. However, with evolving vaccination and the obesity epidemic, progressively more cases are associated with underlying metabolic dysfunction. Pathologically diverse forms of HCC are observed, and recent sequencing analysis has defined common events that target well-known cancer pathways including β-catenin/Axin, TP53, and RB/CDKN2A, as well as frequent aberrations in chromatin remodeling factors. However, there are a myriad of low frequency genetic events that make each HCC case unique. Gene expression profiling approaches have successfully been deployed for prognostic assessment of hepatocellular carcinoma and to detect the earliest stages of disease. Despite more extensive research, systemic treatment for HCC is exceedingly limited, with only a handful of drugs providing benefit. Ongoing clinical trials are attempting to exploit specific biological dependencies of HCC to improve the dismal prognosis. Overall, the future of HCC treatment will rely on an understanding of the interplay between etiological factors, molecular features of disease, and rational therapeutic intervention.",
author = "Knudsen, {Erik S.} and Purva Gopal and Singal, {Amit G.}",
year = "2014",
month = "3",
doi = "10.1016/j.ajpath.2013.10.028",
language = "English (US)",
volume = "184",
pages = "574--583",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The changing landscape of hepatocellular carcinoma

T2 - Etiology, genetics, and therapy

AU - Knudsen, Erik S.

AU - Gopal, Purva

AU - Singal, Amit G.

PY - 2014/3

Y1 - 2014/3

N2 - Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer death and has proved to be highly refractory to treatment. Extensive analysis of the disease has demonstrated that it arises predominantly in response to high-risk etiological challenges, most notably hepatitis virus. However, with evolving vaccination and the obesity epidemic, progressively more cases are associated with underlying metabolic dysfunction. Pathologically diverse forms of HCC are observed, and recent sequencing analysis has defined common events that target well-known cancer pathways including β-catenin/Axin, TP53, and RB/CDKN2A, as well as frequent aberrations in chromatin remodeling factors. However, there are a myriad of low frequency genetic events that make each HCC case unique. Gene expression profiling approaches have successfully been deployed for prognostic assessment of hepatocellular carcinoma and to detect the earliest stages of disease. Despite more extensive research, systemic treatment for HCC is exceedingly limited, with only a handful of drugs providing benefit. Ongoing clinical trials are attempting to exploit specific biological dependencies of HCC to improve the dismal prognosis. Overall, the future of HCC treatment will rely on an understanding of the interplay between etiological factors, molecular features of disease, and rational therapeutic intervention.

AB - Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer death and has proved to be highly refractory to treatment. Extensive analysis of the disease has demonstrated that it arises predominantly in response to high-risk etiological challenges, most notably hepatitis virus. However, with evolving vaccination and the obesity epidemic, progressively more cases are associated with underlying metabolic dysfunction. Pathologically diverse forms of HCC are observed, and recent sequencing analysis has defined common events that target well-known cancer pathways including β-catenin/Axin, TP53, and RB/CDKN2A, as well as frequent aberrations in chromatin remodeling factors. However, there are a myriad of low frequency genetic events that make each HCC case unique. Gene expression profiling approaches have successfully been deployed for prognostic assessment of hepatocellular carcinoma and to detect the earliest stages of disease. Despite more extensive research, systemic treatment for HCC is exceedingly limited, with only a handful of drugs providing benefit. Ongoing clinical trials are attempting to exploit specific biological dependencies of HCC to improve the dismal prognosis. Overall, the future of HCC treatment will rely on an understanding of the interplay between etiological factors, molecular features of disease, and rational therapeutic intervention.

UR - http://www.scopus.com/inward/record.url?scp=84894166118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894166118&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2013.10.028

DO - 10.1016/j.ajpath.2013.10.028

M3 - Article

C2 - 24388934

AN - SCOPUS:84894166118

VL - 184

SP - 574

EP - 583

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -